Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | CD40 | P25942 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922787 | 0.93 | GLP1R (0.42) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493177 | 0.88 | GLP1R (0.53) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493061 | 0.87 | GLP1R (0.48) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493178 | 0.87 | GLP1R (0.48) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493059 | 0.87 | GLP1R (0.48) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493106 | 0.86 | GLP1R (0.56) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL17922793 | 0.86 | GLP1R (0.47) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493162 | 0.86 | GLP1R (0.47) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493127 | 0.85 | GLP1R (0.56) | GLP1RTLR2GNAI3GNAO1GNAI1 | |
| SCHEMBL16493168 | 0.82 | GNAI3 (0.41) | GLP1RTLR2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200791-A1 | GLP-1 Derivatives, and Uses Thereof | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200791-A1 | GLP-1 Derivatives, and Uses Thereof | GLP1R, IAPP, GCG | GLP1R 1/4885TLR2 2716/4885GNAI3 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.